WT1 as a complementary marker of malignant melanoma: An immunohistochemical study of whole sections

Histopathology

Volumn 51, Issue 5, 2007, Pages 605-610

  Wilsher, M ^a   Cheerala, B ^a  

^a DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

Author keywords

Dysplastic naevi; Melanocytic naevi; Melanoma; Wilms' tumour 1 gene and protein

Indexed keywords

BIOLOGICAL MARKER; WT1 PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CARCINOMA IN SITU; CONTROLLED STUDY; DIAGNOSTIC VALUE; DYSPLASTIC NEVUS; EPITHELIOID CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOMA; METASTASIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY; SPINDLE CELL CARCINOMA; TUMOR BIOPSY;

HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS, EPITHELIOID AND SPINDLE CELL; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 35348928723     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02843.x     Document Type: Article

References (21)

1. Rodeck U, Bossler A, Kari C et al. Expression of the WT1 Wilm's tumour gene by normal and malignant human melanocytes. Int. J. Cancer 1994 59 78 82.
2. Havens MA, Chou PM. Expression of WT1 in spitz naevi and melanoma in children. Poster. Abstracts of the Society for Pediatric Pathology Annual Meeting. San Antonio, Texas, USA, February 26-27, 2005. Mod. Pathol. 2005 18 301 314.
3. Perry BN, Cohen C, Govindarajan B, Costonis G, Arbiser JL. Wilms tumour 1 expression present in most melanomas but nearly absent in nevi. Arch. Dermatol. 2006 142 1031 1034.
4. Monoclonal Mouse Anti-Human Wilm's Tumour 1 (WT1), Clone 6F-H2, DAKO. Product information data sheet/package insert accompanying antibody. Ref: 303345-04/03/01-M3561.
5. Hewitt JA, Kessler PM, Campbell CE, Williams BRG. Tissue specific regulation of the WT1 locus. Med. Pediatr. Oncol. 1996 27 456 461.
6. Chen BF, Tzen C-Y, Liang D-C, Liu H-C, Huang Y-W, Fen C-C. Immunohistochemical expression of Wilm's tumour 1 protein in nephroblastoma. J. Chin. Med. Assoc. 2004 67 506 510.
7. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukaemia. Blood 1994 84 3071 3079.
8. Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L. The Wilm's tumor gene is frequently expressed in acute myeloblastic leukaemias may provide a marker for residual blast cells detectable by PCR. Ann. Oncol. 1995 6 811 816.
9. Busam KJ. The use and application of special techniques in assessing melanocytic tumours. Pathology 2004 36 462 469.
10. Blessing K, Sanders DSA, Grant JJH. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB45 in malignant melanoma and melanoma variants. Histopathology 1998 32 139 146.
11. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: Mart-1 and Melan A (The NIH experience). Am. J. Surg. Pathol. 1999 23 607 613.
12. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (antityrosinase) with S-100, HMB45, and A103 (anti-melan-A). J. Clin. Pathol. 2001 54 196 200.
13. Wilkerson AE, Glasgow MA, Hiatt KM. Immunoreactivity of CD99 in invasive malignant melanoma. J. Cutan. Pathol. 2006 33 663 666.
14. De Vries J, Smeets M, de Graaf R et al. Expression of gp100, Mart-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative group. J. Pathol. 2001 193 13 20.
15. Ewanowich C, Brynes RK, Medeiros J, McCourty A, Lai R. Cyclin D1 expression in dysplastic nevi. An immunohistochemical study. Arch. Pathol. Lab. Med. 2001 125 208 210.
16. Ramirez JA, Guitart J, Sambasiva Rao M, Diaz LK. Cyclin D1 expression in melanocytic lesions of the skin. Ann. Diagn. Pathol. 2005 9 185 188.
17. Nakatsura T, Kageshita T, Ito S et al. Identification of Glypican-3 as a novel tumour marker for melanoma. Clin. Cancer Res. 2004 10 6612 6621.
18. Bardessey N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell. Biol. 2001 21 2144 2153.
19. Li W, Sanki A, Karim RZ et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006 38 287 301.
20. Pfaff Smith A, Hoek K, Becker D. Whole-Genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 2005 4 1018 1029.
21. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J. Cutan. Pathol. 2002 29 354 358.